MedicalResearch.com Interview with:
Sabine Luik, M.D.
Senior vice president, Medicine & Regulatory Affairs
Boehringer Ingelheim Pharmaceuticals, Inc.
MedicalResearch.com: What is the background for this study? What are the main findings?
Response: This study is the first real-world, matched head-to-head study comparing all cause healthcare costs and healthcare resource utilization (HCRU) among novel oral anticoagulants (NOACs).
The study analyzed claims data from 70,898 newly-diagnosed NVAF patients who were newly treated with Pradaxa, rivaroxaban or apixaban.
The analysis found that Pradaxa was associated with lower all-cause costs and HCRU compared to rivaroxaban. Compared to apixaban, Pradaxa was associated with similar all-cause costs and hospitalizations, but higher all-cause outpatient and pharmacy HCRU.
MedicalResearch.com: What should clinicians and patients take away from your report?
Response: Hospitalizations and office visits related to NVAF cost the U.S. healthcare system over $6 billion each year. We believe this analysis provides important new information on the economic impact of treatment with Pradaxa.
MedicalResearch.com: What recommendations do you have for future research as a result of this study?
Response: Pradaxa has the longest real-world experience of any available NOAC, and we will continue to evaluate it in real-world settings.
MedicalResearch.com: Is there anything else you would like to add?
Response: While many studies have examined real-world outcomes with NOACs relative to warfarin, this is one of the first studies to compare NOACs against each other in terms of their impact on costs and HCRU. This real-world healthcare economic comparison is not intended to suggest a clinical comparison between NOACs.
The approved labeling for PRADAXA does not include data comparing the product to other NOAC therapies, and there are no clinical trials providing a head-to-head comparison of NOAC therapies.
MedicalResearch.com: Thank you for your contribution to the MedicalResearch.com community.
COMPARISON OF ALL-CAUSE HEALTHCARE RESOURCE UTILIZATION (HCRU) AND COSTS AMONG PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION (NVAF), NEWLY TREATED WITH NEW ORAL ANTI-COAGULANTS (NOACS)
Note: Content is Not intended as medical advice. Please consult your health care provider regarding your specific medical condition and questions.